News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
699,628 Results
Type
Article (41050)
Company Profile (265)
Press Release (658313)
Section
Business (205555)
Career Advice (2019)
Deals (35591)
Drug Delivery (98)
Drug Development (81509)
Employer Resources (169)
FDA (16291)
Job Trends (14920)
News (347504)
Policy (32953)
Tag
Academia (2583)
Alliances (50050)
Alzheimer's disease (1333)
Approvals (16269)
Artificial intelligence (214)
Bankruptcy (359)
Best Places to Work (11686)
Biotechnology (189)
Breast cancer (232)
Cancer (1788)
Cardiovascular disease (132)
Career advice (1681)
CAR-T (130)
Cell therapy (378)
Clinical research (65714)
Collaboration (697)
Compensation (379)
COVID-19 (2607)
C-suite (173)
Data (1690)
Diabetes (223)
Diagnostics (6333)
Earnings (85842)
Employer resources (145)
Events (111854)
Executive appointments (584)
FDA (17242)
Funding (626)
Gene therapy (261)
GLP-1 (668)
Government (4461)
Healthcare (18866)
Infectious disease (2725)
Inflammatory bowel disease (128)
Interviews (312)
IPO (16533)
Job creations (3670)
Job search strategy (1432)
Layoffs (447)
Legal (7951)
Lung cancer (263)
Manufacturing (250)
Medical device (13345)
Medtech (13350)
Mergers & acquisitions (19449)
Metabolic disorders (577)
Neuroscience (1754)
NextGen: Class of 2025 (6558)
Non-profit (4505)
Northern California (2183)
Obesity (316)
Opinion (204)
Patents (175)
People (57292)
Phase I (20487)
Phase II (28925)
Phase III (21571)
Pipeline (783)
Postmarket research (2578)
Preclinical (8664)
Radiopharmaceuticals (242)
Rare diseases (337)
Real estate (5989)
Regulatory (22322)
Research institute (2353)
Resumes & cover letters (350)
Southern California (1878)
Startups (3622)
United States (19260)
Vaccines (641)
Weight loss (216)
Date
Today (111)
Last 7 days (768)
Last 30 days (2704)
Last 365 days (34579)
2025 (5379)
2024 (35484)
2023 (40335)
2022 (51489)
2021 (56039)
2020 (54400)
2019 (46851)
2018 (35306)
2017 (32493)
2016 (31863)
2015 (37928)
2014 (31693)
2013 (26710)
2012 (28882)
2011 (29579)
2010 (27574)
Location
Africa (731)
Arizona (211)
Asia (38256)
Australia (6226)
California (4988)
Canada (1750)
China (415)
Colorado (228)
Connecticut (235)
Europe (82150)
Florida (730)
Georgia (171)
Illinois (463)
Indiana (273)
Maryland (780)
Massachusetts (3800)
Michigan (200)
Minnesota (352)
New Jersey (1416)
New York (1425)
North Carolina (862)
Northern California (2183)
Ohio (176)
Pennsylvania (1130)
South America (1109)
Southern California (1878)
Texas (725)
Utah (154)
Washington State (477)
699,628 Results for "lonza biologics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
What Lonza’s $1.2B Buy of Roche Biologics Plant Means for CDMO Market
The Swiss contract manufacturer’s cash deal for Roche’s facility in Vacaville, California, is one of the world’s largest manufacturing sites for biologics—a major growth driver for Lonza and other CDMOs.
March 28, 2024
·
5 min read
·
Tyler Patchen
Deals
Lonza to Buy Roche Biologics Manufacturing Site in California for $1.2B
The contract manufacturer plans to expand its U.S. footprint with a former Roche facility in Vacaville, California, which Lonza contends is one of the largest biologics manufacturing facilities in the world by volume.
March 20, 2024
·
1 min read
·
Tyler Patchen
Press Releases
TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology
TriLink BioTechnologies, a Maravai™ LifeSciences company and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries.
April 30, 2024
·
2 min read
Press Releases
Cellares Appoints Ossama Eissa, Former Novartis, Lonza and Legend Biopharma Leader, as Chief Operating Officer
November 12, 2024
·
4 min read
Press Releases
MustGrow Signs Exclusive Distribution Agreement with Adjuvants Plus Inc. for Biological Product Line
February 11, 2025
·
8 min read
Business
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), has signed a collaboration agreement with Lonza, a global partner to the pharmaceutical, biotech and nutraceutical markets.
April 4, 2024
·
6 min read
Business
Lonza Projects Flat Sales for 2024 as CDMOs Look to Recover from 2023
While the company expects sales growth to be flat this year, Lonza’s shares jumped around 14% Friday morning after reporting full-year 2023 sales of $7.75 billion, which was 3% above the consensus.
January 26, 2024
·
1 min read
·
Kate Goodwin
Business
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
Lonza (SIX: LONN), a global development and manufacturing partner to the pharma, biotech and nutrition industries, and NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing treatments for amyotrophic lateral sclerosis (ALS) and other severe neurodegenerative diseases.
April 9, 2024
·
7 min read
Press Releases
HCW Biologics Inc. Received NASDAQ Staff Determination Letter
December 23, 2024
·
4 min read
Biotech Bay
Epsilogen and Lonza Announce Successful Large-Scale GMP Manufacturing of MOv18, an IgE Antibody Targeting Ovarian Cancer
Epsilogen and Lonza announced successful completion of Good Manufacturing Practice manufacturing of MOv18 IgE, Epsilogen’s lead IgE antibody drug candidate.
March 5, 2024
·
5 min read
1 of 69,963
Next
